The association between thrombosis and cancer was first brought to our attention by Trousseau's teaching, when he lectured on "phlegmasia alba dolens" in three of his patients with gastric cancer.
1 Since then, we have confirmed that many thrombogenic factors can lead to cancer-associated thrombosis. Alternatively, fibrin and many hemostatic factors can also promote carcinogenesis. One of the earliest observations on the presence of tumor cells in fibrin was made by Billroth, 2 who believed that fibrin plays an important role by which tumors spread. Since then, a causal relationship between fibrinogen, thrombin, or platelets and cancer growth and metastasis has been established by many observations. As a result, there have been numerous attempts to control tumor growth by inhibition of these hemostatic factors. Thus, there appears to be a complex reciprocal interrelationship between cancer and thrombosis. In this issue of Seminars in Thrombosis and Hemostasis, our invited contributors give our readers their expert views on both aspects. The articles being written under this theme are actually appearing in two issues of this journal. Part I (the current issue) begins with an exploration of the thrombogenicity of cancer, as Mahajan et al present a review examining epidemiologic findings of venous thromboembolism in cancer.
3 Within the wide spectrum of cancers, perhaps glioma is one of the most thrombogenic cancer types, as next discussed by Czap et al. 4 Risk factor for thrombosis in brain tumors is discussed next by Riedl and Ay, with interesting recent findings that podoplanin plays a key role. Part II of this theme compendium on thrombosis and cancer will be presented at a future date. Part II will contain other topics on both aspects of this interaction between thrombosis and carcinogenesis. There will be articles that provide further evidence that fibrinogen and platelets can promote carcinogenesis, as well as factors in fibrin gel that enhance angiogenesis. The role of tumor-induced vascular permeability and angiogenesis on coagulation factor and fibrinogen extravasation on protumorigenic stroma formation will also be presented. At the same time, other articles will cover the new approach to management of cancerassociated thrombosis with direct oral anticoagulants. Anticoagulants are not without risks, and thus the risk-benefit considerations will also presented.
Although there have been prior issues of Seminars in Thrombosis and Hemostasis on the topic of cancer and thrombosis, the present compendium represents a novel compilation. We are most excited in assembling these articles in two issues of the journal, and believe that they will provide our readership with a balanced view of the reciprocal and interdependent relationship between cancer and thrombosis.
